Upcoming Alzheimer's Drug Grinds to a Halt
Summary: Amyloid plaques are the result of beta-amyloid protein deposits that build up in-between nerve cells in the brain as neurons deteriorate. Alzheimer's is a degenerative disease that affects the brain. Synaptic connections begin to shrink as neurons die which causes the trademark symptoms that include: decline in both spoken and written speech; decline in the ability to recognize people and objects; decline in judgement/decision making; and decline in motor function. Solanezumab is a drug that was in development to slow the effects of dementia caused by Alzheimer's disease by attacking amyloid plaques within the brain. The results from clinical trials, however, showed that there was no statistically significant difference in the conditions of those given the drug to those who were given a placebo. There are approximately 47 million people who suffer from some form of dementia globally; 60 to 80% of which suffer from Alzheimer's disease. This setback struck the c...